Cases & Deals

Rgenix raises capital in Series C round

Clients Rgenix, Inc.

Jones Day represented Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, in connection with its issuance of $40 million of Series C Convertible Preferred Stock in a private placement to Lepu Medical, Oceanpine Capital and WuXi AppTec’s Corporate Venture Fund, Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments, LLC, and the Partnership Fund for New York City’s Innovate NY Fund and associated entities.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.